- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
- Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
- Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
- Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
- Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
- Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
- Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
- Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
More ▼
Key statistics
On Tuesday, Athira Pharma Inc (ATHA:NSQ) closed at 1.97, 48.12% above the 52 week low of 1.33 set on Nov 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.00 |
---|---|
High | 2.02 |
Low | 1.95 |
Bid | 1.94 |
Offer | 2.43 |
Previous close | 1.97 |
Average volume | 142.42k |
---|---|
Shares outstanding | 38.33m |
Free float | 31.77m |
P/E (TTM) | -- |
Market cap | 75.50m USD |
EPS (TTM) | -3.09 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 21:00 BST.
More ▼